These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 23334667)

  • 1. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
    Brastianos PK; Horowitz PM; Santagata S; Jones RT; McKenna A; Getz G; Ligon KL; Palescandolo E; Van Hummelen P; Ducar MD; Raza A; Sunkavalli A; Macconaill LE; Stemmer-Rachamimov AO; Louis DN; Hahn WC; Dunn IF; Beroukhim R
    Nat Genet; 2013 Mar; 45(3):285-9. PubMed ID: 23334667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
    Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
    Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
    Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
    Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic landscape of meningioma.
    Yuzawa S; Nishihara H; Tanaka S
    Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
    Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
    Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic characterization and mutational profiling of foramen magnum meningiomas: a multi-institutional study.
    Hua L; Alkhatib M; Fujio S; Alhasan B; Herold S; Zeugner S; Zolal A; Hijazi MM; Clark VE; Wakimoto H; Shankar GM; Brastianos PK; Barker FG; Cahill DP; Ren L; Eyüpoglu IY; Gong Y; Schackert G; Juratli TA
    J Neurosurg; 2024 Jul; 141(1):72-78. PubMed ID: 38277657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
    Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
    Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
    Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
    J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.
    Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S
    Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.
    Strickland MR; Gill CM; Nayyar N; D'Andrea MR; Thiede C; Juratli TA; Schackert G; Borger DR; Santagata S; Frosch MP; Cahill DP; Brastianos PK; Barker FG
    J Neurosurg; 2017 Aug; 127(2):438-444. PubMed ID: 27885953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
    Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
    Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
    Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
    Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-NF2 mutations in meningioma.
    Benmaamar R
    Lancet Oncol; 2013 Mar; 14(3):e91. PubMed ID: 23580960
    [No Abstract]   [Full Text] [Related]  

  • 15. Germline and somatic mutations in meningiomas.
    Smith MJ
    Cancer Genet; 2015 Apr; 208(4):107-14. PubMed ID: 25857641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical potential of meningioma genomic insights: a practical review for neurosurgeons.
    Karsy M; Azab MA; Abou-Al-Shaar H; Guan J; Eli I; Jensen RL; Ormond DR
    Neurosurg Focus; 2018 Jun; 44(6):E10. PubMed ID: 29852774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-genome sequencing identifies new genetic alterations in meningiomas.
    Tang M; Wei H; Han L; Deng J; Wang Y; Yang M; Tang Y; Guo G; Zhou L; Tong A
    Oncotarget; 2017 Mar; 8(10):17070-17080. PubMed ID: 28177878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in
    Adams CL; Ercolano E; Ferluga S; Sofela A; Dave F; Negroni C; Kurian KM; Hilton DA; Hanemann CO
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
    Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
    Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF2 tumor suppressor gene: a comprehensive and efficient detection of somatic mutations by denaturing HPLC and microarray-CGH.
    Szijan I; Rochefort D; Bruder C; Surace E; Machiavelli G; Dalamon V; Cotignola J; Ferreiro V; Campero A; Basso A; Dumanski JP; Rouleau GA
    Neuromolecular Med; 2003; 3(1):41-52. PubMed ID: 12665675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.